#16
|
||||
|
||||
Êàê ìàòåðè ïîñëå áàðèàòðè÷åñêèõ îïåðàöèé êîðìÿò ñâîèõ äåòåé
Àìåðèêàíñêèå èññëåäîâàòåëè: ìàòåðè ïîñëå áàðèàòðè÷åñêîé õèðóðãèè ãîðàçäî ÷àùå ñîáëþäàþò ïðèíöèïû çäîðîâîãî ïèòàíèÿ ïðè êîðìëåíèè ñâîèõ äåòåé, ÷åì äî ìàòåðè ñ îæèðåíèåì, ó êîòîðûõ íå áûëî áàðèàòðè÷åñêîé îïåðàöèè.
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#17
|
||||
|
||||
Ýòî íåïðèÿòíî : íå èñêëþ÷åíî , ÷òî áàðèàòðè÷åñêàÿ õèðóðãèÿ óâåëè÷èâàåò ðèñê ðåòèíîïàòèè .
Seven of 40 diabetes patients screened about a year before and again after bariatric surgery progressed, for a rate of 17.5%, compared with the 2% to 4% of diabetes patients who develop retinopathy each year. A review of Thomas RL, et al. ADA 2013; Abstract 155-OR posted at [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ].
__________________
Ã.À. Ìåëüíè÷åíêî |
#18
|
||||
|
||||
Âñå áîëüøå ïóáëèêàöèé, ÷òî ïîñëå âûïîëíåíèÿ Roux-en-Y gastric bypass ïðèåì ïðåïàðàòà æåëåçà âíóòðü ÍÅ êîððèãèðóåò àíåìèè è ïàöèåíòû íóæäàþòñÿ â â/â ââåäåíèè:
Iron management was inadequate. Hematologic values often were deficient for sustained periods. Initially, few patients received intravenous iron after oral iron failure, many received no iron supplementation, and there was high use of blood transfusions. Subsequently, administration of intravenous iron was beneficial. Surg Obes Relat Dis. 2013 Feb 13. Management of iron deficiency and anemia after Roux-en-Y gastric bypass surgery: an observational study. --- Iron Deficiency After Roux-en-Y Gastric Bypass: Insufficient Iron Absorption from Oral Iron Supplements. Gesquiere I, Lannoo M, Augustijns P, Matthys C, Van der Schueren B, Foulon V. Obes Surg. 2013 Aug 6. --- ...the use of IV iron has begun to gain popularity in the treatment of iron deficiency anemia (IDA) associated with two conditions that are being seen more frequently than in years past: patients who are status post gastric bypass procedure and those with inflammatory bowel disease. World J Gastrointest Pharmacol Ther. 2013 Aug 6;4(3):49-53. Emerging causes of iron deficiency anemia refractory to oral iron supplementation.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#19
|
||||
|
||||
Äåéñòâèòåëüíî, íèêàêèõ ñîìíåíèé íåò, ÷òî ïîñëå øóíòèðóþùèõ îïåðàöèé (æåëóäî÷íîå øóíòèðîâàíèå è ÁÏØ) ìîãóò ðàçâèâàòüñÿ ðàçëè÷íûå ìåòàáîëè÷åñêèå äåôèöèòû. Îñîáåííî ÷àñòî ïîäîáíûå ÿâëåíèÿ èìåþò ìåñòî ó ïàöèåíòîâ ñ íèçêîé äèñöèïëèíîé è îòâåòñòâåííîñòüþ. Ìû âñåãäà ïðåäóïðåäæàåì âñåõ ïàöèåíòîâ î íåîáõîäèìîñòè ðåãóëÿðíîãî ïðèåìà âèòàìèíîâ è ìèêðîýëåìåíòîâ äëÿ ïðîôèëàêòèêè ïîäîáíûõ ÿâëåíèé, à òàêæå îá îáÿçàòåëüíîé íåîáõîäèìîñòè ðåãóëÿðíî ñäàâàòü àíàëèçû äëÿ òîãî, ÷òîáû âîâðåìÿ âûÿâèòü ðàçâèâàþùèåñÿ ïðîáëåìû. Òåì íå ìåíåå î÷åíü ìíîãî òàêèõ "ïîôèãèñòîâ", êîòîðûå ïîòîì ãîâîðÿò "ÿ íè÷åãî íå ïðèíèìàþ è íèêàêèõ àíàëèçîâ íå ñäàþ, òàê êàê îòëè÷íî ñåáÿ ÷óâñòâóþ". À ñêðûòûå äåôèöèòû ìîãóò íàêàïëèâàòüñÿ è ïîòîì âñå ýòî îáðóøèâàåòñÿ, êàê ñíåæíûé êîì.
 ñâÿçè ñ ýòèì î÷åíü âàæíà îöåíêà ëè÷íîñòè ïàöèåíòà. Ëþäÿì, ñêëîííûì ê òàêîìó "ïîôèãèçìó" ëó÷øå íå äåëàòü îïåðàöèé, òðåáóþùèõ âûñîêîé òåîðåòè÷åñêîé ïîäãîòîâêè ñàìîãî ïàöèåíòà (â ïëàíå ïîíèìàíèÿ èì ñóòè îïåðàöèè è ïîòåíöèàëüíûõ ïðîáëåì â áóäóùåì) è âûñîêîé îòâåòñòâåííîñòè. Òàêèå ïîôèãèñòû ïîòîì íå áóäóò íè àíàëèçû ñäàâàòü, íè òàáëåòêè ïðèíèìàòü, íè æåëåçî êîëîòü ïðè íåîáõîäèìîñòè. Äðóãîé âîïðîñ, êàê òàêèõ ïîôèãèñòîâ âû÷èñëèòü äî îïåðàöèè. Áåñåäû ñ ïñèõîòåðàïåâòàìè òîæå íå îñîáî ïîìîãàþò. Ìû äàâíî óæå ÷óâñòâóåì, ÷òî íàçðåëà íåîáõîäèìîñòü ðàçðàáîòêè ñòàíäàðòèçèðîâàííûõ îïðîñíèêîâ äëÿ ïðîãíîçèðîâàíèÿ òàêîãî ïîâåäåíèÿ. Âåðîÿòíî, ëþäÿì ñ íèçêèì óðîâíåì îòâåòñòâåííîñòè ëó÷øå áóäåò äåëàòü ÷òî-òî ïîïðîùå, íàïðèìåð ðóêàâíóþ ãàñòðîïëàñòèêó. |
#20
|
||||
|
||||
åøå ïî òåìå â ïîëíîé âåðñèè:
Hematological Disorders following Gastric Bypass Surgery: Emerging Concepts of the Interplay between Nutritional Deficiency and Inflammation [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#21
|
||||
|
||||
Äåòñêàÿ áàðèàòðèÿ
Ïîáèò íîâûé ðåêîðä ïî ñíèæåíèþ âîçðàñòà ïàöèåíòîâ áàðèàòðè÷åñêîé õèðóðãèè. Ïðåäûäóùèé ðåêîðä ñîñòàâëÿë 6 ëåò. Íà ýòîò ðàç áàðèàòðè÷åñêèì ïàöèåíòîì ñòàë Ðèøè Õàòàó, 4-ëåòíèé ìàëü÷èê èç Èíäèè.  ñâîè 4 ãîäà îí âåñèë ïî÷òè 50 êã. Ïîêàçàíèåì ê îïåðàöèè ñòàëî áûñòðî ïðîãðåññèðîâàâøåå óõóäøåíèå çäîðîâüÿ. Äîñòàòî÷íî ñêàçàòü, ÷òî îí ìîã ñïàòü â îáû÷íîì ïîëîæåíèè íå áîëåå 10 ìèíóò, ïîñëå ÷åãî ó ïàäàëî íàñûùåíèå êðîâè êèñëîðîäîì. Ïðèäåðæèâàòüñÿ äèåòû ìàëü÷èê íå ìîã, òàê êàê ó íåãî èìååòñÿ ãåíåòè÷åñêîå çàáîëåâàíèå - ñèíäðîì Ïðàäåðà-Âèëëè (ñíèæåíèå èíòåëëåêòà â ñî÷åòàíèè ñ ïîñòîÿííûì ÷óâñòâîì ãîëîäà), ÷òî íå äàåò åìó âîçìîæíîñòè êîíòðîëèðîâàòü ñâîå ïèùåâîå ïîâåäåíèå.
[Èçîáðàæåíèÿ äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì] Ìàëü÷èêó ñäåëàíà îïåðàöèÿ ðóêàâíîé ãàñòðîïëàñòèêè - ÑËÈÂ. Íà ñíèìêå ìàëåíüêèé ïàöèåíò, åãî äîêòîð (ñëåâà íà ñíèìêå) è ïàïà (ñïðàâà íà ñíèìêå). Ñåé÷àñ ìàëü÷èê åñò ïðèìåðíî â òðè ðàçà ìåíüøå, ÷åì äî îïåðàöèè. |
#22
|
||||
|
||||
Èñïîëüçîâàíèå ÑÒà ïðè ñ-ìå Ïðàäåðà - Âèëëè èìååò íåêîòîðûå îãðàíè÷åíèÿ - ïðèìåíèòåëüíî ê ýòîìó ìàëü÷èêó èñïîëüçîâàëñÿ ëè ïðåïàðàò?
__________________
Ã.À. Ìåëüíè÷åíêî |
|
#23
|
||||
|
||||
Öèòàòà:
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#24
|
||||
|
||||
Áàðèàòðè÷åñêàÿ õèðóðãèÿ ïî ñðàâíåíèþ ñ íåõèðóðãè÷åñêèìè ìåòîäàìè êîððåêöèè îæèðåíèÿ - ðåçóëüòàòû ìåòà-àíàëèçà
Eligible studies were randomised controlled trials with ≥6 months of follow-up that included individuals with a body mass index ≥30, compared current bariatric surgery techniques with non-surgical treatment, and reported on body weight, cardiovascular risk factors, quality of life, or adverse events. The meta-analysis included 11 studies with 796 individuals (range of mean body mass index at baseline 30-52). Individuals allocated to bariatric surgery lost more body weight (mean difference -26 kg (95% confidence interval -31 to -21)) compared with non-surgical treatment, had a higher remission rate of type 2 diabetes (relative risk 22.1 (3.2 to 154.3) in a complete case analysis; 5.3 (1.8 to 15.8) in a conservative analysis assuming diabetes remission in all non-surgically treated individuals with missing data) and metabolic syndrome (relative risk 2.4 (1.6 to 3.6) in complete case analysis; 1.5 (0.9 to 2.3) in conservative analysis), greater improvements in quality of life and reductions in medicine use (no pooled data). Plasma triglyceride concentrations decreased more (mean difference -0.7 mmol/L (-1.0 to -0.4) and high density lipoprotein cholesterol concentrations increased more (mean difference 0.21 mmol/L (0.1 to 0.3)). Changes in blood pressure and total or low density lipoprotein cholesterol concentrations were not significantly different. There were no cardiovascular events or deaths reported after bariatric surgery. The most common adverse events after bariatric surgery were iron deficiency anaemia (15% of individuals undergoing malabsorptive bariatric surgery) and reoperations (8%). Compared with non-surgical treatment of obesity, bariatric surgery leads to greater body weight loss and higher remission rates of type 2 diabetes and metabolic syndrome. However, results are limited to two years of follow-up and based on a small number of studies and individuals. BMJ. 2013 Oct 22;347:f5934. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#25
|
||||
|
||||
Ðàäóþùàÿ ( Stanford University) - íîâîñòü : ó 51 ïåðåíåñøåãî áàðèàòðè÷åñêîå âìåøàòåëüñòâî ïàöèåíòà ãîä ñïóñòÿ ïîñëå îïåðàöèè , “ñòàëè äëèííåå òåëîìåðû ( ïî ñðàâíåíèþ ñ ÷åì , íåÿñíî - íî âðîäå êàê ê âå÷íîé æèçíè ) ,ñèå ïðîèçîøëî ó òåõ , ó êîãî õóæå âñåãî áûëè ïàðàìåòðû êàðäèîâàñêóëÿðíîãî ðèñêà äî îïåðàöèè.
Îãîð÷àþùàÿ íîâîñòü : ïåðåíåñøèå ýòè îïåðàöèè æåíùèíû ÷àùå ðîæäàþò íåäîíîøåííûõ è ìàëîâåñíûõ äåòåé
__________________
Ã.À. Ìåëüíè÷åíêî |
#26
|
||||
|
||||
Ïîïûòêà ïðèâåñòè â ïðèëè÷íûé âèä ïîñòóïàþùóþ èíôîðìàöèþ.
ÀÍÀ/ ÀÑÑ/ ÒÎS Obesity Guideline âñåðüåç ïîñòàâèëè çàäà÷ó îöåíèâàòü àäåêâàòíî ðåçóëüòàòû - ñðàâíåíèå õèðóðãè÷åñêèõ ìåòîäîâ â ñîïîñòàâëåíèè ñ òåðàïåâòè÷åñêèìè ìèíèìóì ïîñëå 2-õ ëåòíåãî íàáëþäåíèÿ , äëÿ îáñåðâàöèîííûõ ñ áîëåå ÷åì 10 - ëåòíåé ïðîäîëæèòåëüíîñòüþ -êîãîðòû ìèíèìóì 100 ÷åëîâåê ( ðàçíûå òèïû îïåðàöèé) , à äëÿ îáñåðâàöèîííûõ äðóãîé ïðîäîëæèòåëüíîñòè - ìèíèìóì 500 ÷åëîâåê, êàê - òî êðóòî âçÿëèñü íà îöåíêó ñàìîãî äèçàéíà èññëåäîâàíèé  èòîãå Ïîçèöèÿ 3.5.1 - ÅS 1 ïîòåðÿ ìàññû òåëà ïðè ÈÌÒ áîëåå 30 çà 2-3 ãîäà ïðè âñåõ õèðóðãè÷åñêèõ ïðîöåäóðàõ ñîñòàâëÿåò 20-35 ïðîöåíòîâ ñ ðàçëè÷èÿìè ìåæäó ïðîöåäóðàìè îò 14 äî 37 Äîêàçàòåëüñòâà âûñîêîãî óðîâíÿ ES 2 - ÷åðåç 10 ëåò ïîñëå ðàçâè÷íûõ âìåøàòåëüñòâ ( ïðåèìóùåñòâåííî ãàñòðîïëàñòèêà) - 16 ïðîöåíòîâ ( ñðåäíÿÿ ïðèáàâêà 7 ïðîöåíòîâ)? Óðîâåíü äîêàçàòåëüíîñòè íèçêèé
__________________
Ã.À. Ìåëüíè÷åíêî |
#27
|
||||
|
||||
Ïñèõîëîãè÷åñêèå èçìåíåíèÿ ïîñëå îïåðàöèè Sleeve
Èñïàíñêèå èññëåäîâàòåëè èçó÷èëè ïñèõîëîãè÷åñêèå èçìåíåíèÿ, êîòîðûå èìåþò ìåñòî ïîñëå îïåðàöèè ðóêàâíîé ãàñòðîïëàñòèêè (ÑËÈÂ). 46 ïàöèåíòîâ áûëè äåòàëüíî ïðîòåñòèðîâàíû ïî ìíîæåñòâó ïñèõîëîãè÷åñêèõ øêàë äî îïåðàöèè è ÷åðåç ãîä ïîñëå íåå. Áûëà ïîëó÷åíà ïîçèòèâíàÿ äèíàìèêà ïî÷òè ïî âñåì øêàëàì, êðîìå ïåðôåêöèîíèçìà. Îñîáåííî âûðàæåííîå óëó÷øåíèå îòìå÷àëîñü ïî øêàëàì áóëèìèè (89%) è íåóäîâëåòâîðåííîñòè ñâîèì òåëîì (55%).
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#28
|
||||
|
||||
Õîëåöèñòèò è áàðèàòðèÿ
Àìåðèêàíñêèå èññëåäîâàòåëè èçó÷àëè ÷àñòîòó õîëåöèñòýêòîìèè ïîñëå áàðèàòðè÷åñêèõ îïåðàöèé. Ñðîê íàáëþäåíèÿ ñîñòàâèë îêîëî 5 ëåò. Îêàçàëîñü, ÷òî ïîñëå ÆØ óäàëåíèå æåë÷íîãî ïóçûðÿ ïîòðåáîâàëîñü ó 10% ïàöèåíòîâ, ïîñëå ÑËÈÂà ó 3.5% è ïîñëå áàíäàæèðîâàíèÿ ó 3% ïàöèåíòîâ. Àâòîðû äåëàþò âûâîä, ÷òî íåîáõîäèìîñòè â ðóòèííîì óäàëåíèè æåë÷íîãî ïóçûðÿ ïðè áàðèàòðè÷åñêèõ îïåðàöèÿõ íåò. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#29
|
||||
|
||||
Óðîâåíü çíàíèé îáùèõ õèðóðãîâ î áàðèàòðèè
Ïîëüñêèå èññëåäîâàòåëè èçó÷àëè, ÷òî çíàþò îáùèå õèðóðãè î áàðèàòðè÷åñêîé õèðóðãèè. Àíêåòû áûëè ðîçäàíû 134 õèðóðãàì íà îäíîé èç êîíôåðåíöèé. Íà îñíîâàíèè ïîëó÷åííûõ îòâåòîâ ñäåëàíû íåóòåøèòåëüíûå âûâîäû: ïðàâèëüíûå ïðåäñòàâëåíèÿ î áàðèàòðè÷åñêîé õèðóðãèè èìåþò òîëüêî 25% îáùèõ õèðóðãîâ.
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Õîòÿ ýòî èññëåäîâàíèå îòíîñèòñÿ ê Ïîëüøå, âðÿä ëè ðîññèéñêèå õèðóðãè çíàþò áîëüøå. Ñêîðåå ñîâñåì íàîáîðîò. |
#30
|
||||
|
||||
Âîçìîæíî áàðèàòðè÷åñêàÿ õèðóðãèÿ ñíèæàåò ðèñê áîëåçíè Àëüöãåéìåðà:
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |